The Wegovy pill: oral semaglutide for weight loss and when it's coming to the UK

The Wegovy pill is real, it works, and it's already available in the United States. For anyone in the UK who has been following the GLP-1 space, the obvious question is: when does it arrive here?

The short answer is late 2026 for regulatory approval, with NHS access more likely in 2027. But there's quite a lot more to understand before deciding whether the pill would actually be right for you, especially if you're already on injectable Wegovy or Mounjaro, or if needle aversion has been the main barrier to starting treatment.

What is the Wegovy pill?#

The Wegovy pill is a daily oral tablet containing semaglutide 25 mg. It's the same active drug as injectable Wegovy, just in tablet form. The FDA approved it in December 2025, and it launched in the US in January 2026.

Semaglutide works by mimicking GLP-1, a hormone the gut releases after eating. This reduces appetite, slows gastric emptying, and produces what many patients describe as a quietening of constant food-related thoughts. The mechanism is identical whether you're injecting or swallowing it.

The challenge with making semaglutide into a tablet is that it's a peptide (a chain of amino acids), and stomach acid would normally destroy it before it reaches the bloodstream. Novo Nordisk solved this using an absorption enhancer called SNAC (salcaprozate sodium), which protects the molecule and helps it cross the stomach lining. This technology is the same one used in Rybelsus, the existing lower-dose oral semaglutide used for type 2 diabetes in the UK.

The pill comes in four strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. You start at the lowest dose and increase every 30 days, reaching the 25 mg maintenance dose after about 12 weeks.

When will it be available in the UK?#

Novo Nordisk submitted the 25 mg oral semaglutide to the European Medicines Agency and the MHRA during the second half of 2025. MHRA approval is expected in late 2026.

Once the MHRA approves a medicine, it's licensed for prescribing in the UK, but NHS funding requires a separate step. NICE carries out a health technology assessment, weighing the clinical benefit against the cost to the NHS. For injectable Wegovy, this process took around nine months after MHRA approval. If the same pattern holds, the Wegovy pill could reach the NHS in 2027, though access will likely roll out gradually through specialist weight management services.

Private providers will almost certainly offer it before the NHS does. That's what happened with both injectable Wegovy and Mounjaro, and there's no reason to expect a different pattern here.

If you're considering weight loss treatment now rather than waiting, injectable Wegovy and Mounjaro are both available in the UK through private providers, with NHS access also available for those who meet the NICE eligibility criteria.

How effective is the Wegovy pill?#

The key evidence comes from the OASIS 4 trial, published in the New England Journal of Medicine in September 2025. The trial enrolled 307 adults with obesity or overweight (plus at least one weight-related condition) without type 2 diabetes. Participants took either oral semaglutide 25 mg or a placebo daily for 71 weeks, with the primary weight outcome measured at week 64.

The results were clear. People taking the pill lost an average of 13.6% of their body weight, compared to 2.2% on placebo. Among those who completed the full course at maintenance dose, average weight loss reached 16.6%.

Breaking it down further:

• Around 79% of participants lost at least 5% of their body weight
• Around 60% lost at least 10%
• Around 43% lost at least 15%

For comparison, injectable Wegovy at 2.4 mg produced an average weight loss of 14.9% over 68 weeks in the STEP 1 trial. The numbers are broadly comparable. The higher-dose injectable (7.2 mg, studied in the STEP UP trial) produces greater weight loss than either the pill or the standard injection, which is worth knowing if you're comparing options.

OASIS 4 also showed improvements in waist circumference, blood sugar, lipids, and inflammatory markers, reinforcing that the weight loss translates into meaningful cardiometabolic benefit, not just a change on the scales.

The Wegovy pill versus the injection: how they actually compare#

The effectiveness is similar, but there are practical differences worth thinking through honestly.

In favour of the pill:

• No needles, which matters a lot for people with needle aversion
• Easier to travel with (no sharps, no refrigeration requirements during transit)
• No injection site reactions
• A daily tablet fits naturally into an existing medication routine for some people

In favour of the injection:

• Weekly dosing is simpler for many people than remembering a daily pill
• No fasting window (more on this below)
• The higher-dose injectable (7.2 mg) may produce greater weight loss than the oral 25 mg
• Already available in the UK right now

For people who are managing well on the injection, there's no strong clinical reason to switch to the pill. The choice is largely practical.

How to take the Wegovy pill correctly#

This is one area where the pill genuinely requires more attention than the injection. Because semaglutide absorption depends on the SNAC enhancer working under specific conditions, taking the tablet incorrectly reduces how much drug gets into your system.

The rules are straightforward but non-negotiable:

• Take it first thing in the morning, on an empty stomach
• Use no more than 120 ml of water (roughly half a glass)
• Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications
• Swallow the tablet whole, do not crush or chew it

If you miss a dose, skip it and take the next one the following morning as usual. Taking two tablets on the same day is not recommended.

The 30-minute window and your other medications#

This is something a pharmacist would flag immediately, and it's genuinely important. The 30-minute fasting window isn't just about food. It applies to other oral medications too, which creates a practical challenge for people who take morning medications that themselves need to be taken on an empty stomach.

The most clinically significant interactions to be aware of:

• Levothyroxine (used for an underactive thyroid) must be taken on an empty stomach and is highly sensitive to timing. Taking the Wegovy pill and levothyroxine simultaneously could affect absorption of both. The standard advice would be to separate them, but the exact timing needs to be confirmed with your prescriber.
• Bisphosphonates (alendronate, risedronate for osteoporosis) also require an empty stomach and a 30-minute wait. Stacking these with the Wegovy pill in the same morning window would be difficult to manage safely.
• Proton pump inhibitors (omeprazole, lansoprazole) are commonly taken in the morning; the timing interaction is less critical than with levothyroxine, but worth discussing.

If you take any regular morning medication, particularly levothyroxine or a bisphosphonate, raise this with your prescriber or pharmacist before starting the Wegovy pill. It can usually be planned around, but it needs specific guidance based on your full medication list.

How much will the Wegovy pill cost in the UK?#

UK pricing hasn't been announced yet. The US cash prices at launch ranged from around $170 to $500 per month depending on dose stage, but US and UK pharmaceutical pricing are very different markets. Injectable Wegovy retails privately in the UK at roughly £150 to £250 per month, which is substantially below the US equivalent.

A reasonable expectation is that the Wegovy pill will be priced similarly to injectable Wegovy once it reaches the UK private market, somewhere in that £150 to £250 range. Whether that holds will depend on Novo Nordisk's UK pricing strategy and how NICE values it during the health technology assessment.

Will the Wegovy pill be available on the NHS?#

NHS access requires two things: MHRA approval (expected late 2026) followed by a positive NICE recommendation (most likely 2027 at the earliest).

For context, the existing injectable Wegovy is available on the NHS for adults with a BMI of 35 or above and at least one weight-related condition, typically through specialist Tier 3 or Tier 4 weight management services. Access varies by region, and waiting lists can be long.

The oral version would likely follow similar eligibility criteria, but NICE will conduct its own assessment rather than automatically extending coverage from the injectable form.

If you're trying to work out whether you'd qualify under the NHS criteria for the injectable version while you wait, a pharmacist-led consultation can help clarify this based on your individual circumstances.

Side effects#

The side effect profile of the Wegovy pill mirrors that of the injection, with most effects involving the digestive system.

In OASIS 4, 74% of participants on the pill reported gastrointestinal side effects, compared to 42% on placebo. The most common were nausea, diarrhoea, and vomiting. Most cases were mild to moderate, tended to worsen during dose increases, and improved as the body adjusted.

Serious adverse events were actually less common with oral semaglutide (3.9%) than with placebo (8.8%) in OASIS 4, which is a consistent finding across semaglutide trials.

The same contraindications that apply to injectable Wegovy apply here. The pill is not recommended for people with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, a history of pancreatitis, or those who are pregnant or breastfeeding. People with active inflammatory bowel disease, including Crohn's disease or ulcerative colitis, should discuss the risks carefully with their prescriber given the already elevated GI side effect rate.

How the Wegovy pill compares to Rybelsus#

Rybelsus is oral semaglutide and is already licensed and available in the UK, so people sometimes ask whether it's essentially the same thing as the Wegovy pill.

It is the same drug, but at a lower dose and for a different indication. Rybelsus is approved for type 2 diabetes management at doses up to 14 mg. At that dose, weight loss is typically modest, around 2 to 4 kg over six to twelve months in diabetes trials. The Wegovy pill at 25 mg is specifically approved for weight management and produces substantially greater weight loss.

If you take Rybelsus for type 2 diabetes, the Wegovy pill is not an add-on treatment. It's the same drug at a higher dose, and any change would need to be managed by your prescriber.

Other weight loss options available in the UK right now#

While the Wegovy pill works its way through UK regulatory review, the licensed options for weight management in the UK are:

• Injectable Wegovy (semaglutide 2.4 mg and 7.2 mg) - available privately and on the NHS
• Mounjaro (tirzepatide) - available privately and beginning to roll out on the NHS
• Orlistat - available on prescription and over the counter
• Mysimba (naltrexone/bupropion) - available on prescription

Foundayo (orforglipron), a novel oral GLP-1 that doesn't require the fasting window, received FDA approval in April 2026 and is currently in MHRA review. UK availability is expected in 2027.

If needle aversion is the main reason you've been putting off starting a GLP-1, it's worth having a proper conversation about whether injectable Wegovy or Mounjaro might actually suit you better than waiting. Many people who were convinced they couldn't manage injections find the weekly auto-injector pen straightforward in practice.

Who the Wegovy pill is most likely to suit#

The pill will be a genuinely good option for a specific group of people:

• Those with needle aversion who have avoided GLP-1 treatment for that reason
• Frequent travellers who find managing injectable pens difficult
• People who already take a daily oral medication and want everything in one morning routine

For people who are already on the injection and doing well, switching to the pill introduces a daily fasting routine without a clear clinical gain. The effectiveness is broadly comparable, not better.

If you're ready to explore weight loss treatment options now, Totiva's pharmacist-led consultations can help you work out whether injectable Wegovy, Mounjaro, or another treatment is the right fit while the Wegovy pill completes its UK regulatory journey.

For anyone who wants to get started sooner rather than later, you can begin a weight loss consultation with Totiva here. A pharmacist will review your health history, discuss your options honestly, and help you find a treatment that actually fits your life.